Medical device company Iantrek has closed on $23 million of series B financing.
Iantrek specializes in ophthalmic devices and technology. The new financing will be used for clinical introduction and further studies of Iantrek's micro-interventional glaucoma surgical devices, according to an Aug. 30 Iantrek news release.
"There remains a significant unmet clinical need to provide safe and effective micro-interventional tools for aqueous outflow management," said Sean Ianchulev, MD, founder of Iantrek. "We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies. With two commercially ready MIGS platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery."